Form 4: Integra LifeSciences Executive Chairman Stuart Essig Reports Share Transactions

Stuart Essig, Executive Chairman of Integra LifeSciences, reports the acquisition of shares through a Grantor Retained Annuity Trust (GRAT) and updates beneficial ownership.

Summary

• On May 9, 2025, Stuart Essig, the Executive Chairman of the Board at Integra LifeSciences Holdings Corp, reported transactions involving the company's common stock.
• Essig acquired 6,939 shares and 24,898 shares of common stock at $0 per share.
• These acquisitions increased his direct holdings to 672,156 shares.
• Essig also indirectly owns 400,000 shares through a GRAT, 500,000 shares through another GRAT, and 213,115 shares through a trust.
• Additionally, 152,397 shares were distributed from a Grantor Retained Annuity Trust (GRAT) to Essig.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the document primarily reports transactions without expressing any positive or negative outlook.

Positives

• The increase in share ownership could be interpreted positively, signaling confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider trading regulations and provides transparency regarding the holdings and transactions of company executives.

Key Dates

Keywords

Integra LifeSciences, Stuart Essig, Executive Chairman, Share Transactions, Beneficial Ownership, Form 4, GRAT, Securities